Aardvark Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
A novel oral small molecule targets gut-brain signaling to regulate hunger, with a single agent for rare disease and a combination for obesity. Early clinical and preclinical data show promising weight loss and body composition effects, with a phase III trial underway in Prader-Willi syndrome.
-
Key programs target Prader-Willi syndrome and obesity, with ARD-101 in phase 3 and ARD-201 in phase 2. Phase 3 data for Prader-Willi is expected in Q3 2026, while preliminary obesity data is anticipated by end of next year.
-
-
ARD-101, a gut-restricted oral drug, showed rapid and robust reduction in hyperphagia and metabolic improvements in Prader-Willi syndrome, with phase III results expected in Q3 2026. The combination ARD-201 demonstrated strong preclinical weight loss, and clinical obesity data are anticipated next year.
-
ARD-101 is progressing into a global phase III HERO trial for Prader-Willi Syndrome, following phase II results showing significant hunger reduction and improved body composition. The trial is designed for broad accessibility and minimal disruption, with strong advocacy support and a focus on addressing major unmet needs in hyperphagia and related symptoms.
-
A novel oral, gut-restricted therapy showed rapid and significant reductions in hunger and improved body composition in Prader-Willi syndrome, with a robust Phase III trial underway. Preclinical data for a combination therapy indicate weight loss efficacy comparable to leading injectables.
-
The company is advancing a gut-restricted oral drug for Prader-Willi syndrome, showing strong phase II results and a robust safety profile, with phase III trials underway and expansion to younger patients. In obesity, a combination therapy targets weight maintenance and loss, with pivotal trials starting soon. Cash reserves support operations into 2027.
-
The session detailed advances in gut-brain signaling drugs for obesity and Prader-Willi, highlighting strong preclinical and early clinical results, new trial designs to address weight regain, and robust community engagement. Key data readouts are expected in 2026.
-
ARD-101 stimulates natural gut hormones to address hyperphagia in Prader-Willi syndrome, showing strong Phase II efficacy and a favorable safety profile. Phase III incorporates refined criteria and aims for regulatory approval with a single pivotal study, while expansion into hypothalamic and general obesity is planned.
-
A recent IPO with $150 million in cash is advancing a gut-targeted therapy for hunger-driven disorders, with pivotal trials underway in Prader-Willi, hypothalamic obesity, and general obesity. Early data show strong efficacy and safety, and the approach may complement GLP-1s.
-
A novel gut-restricted therapy targeting hunger pathways is in pivotal phase III for Prader-Willi syndrome, with additional phase II trials in hypothalamic and general obesity planned. Early data show strong efficacy and safety, with multiple readouts expected in 2026.